ENTITY
TYK Medicines

TYK Medicines (2410 HK)

47
Analysis
Health Care • China
TYK Medicines is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of small molecule pharmaceutical products. The company's pipeline includes drug candidates for treating various cancers, such as breast cancer, prostate cancer, and solid tumors. TYK Medicines was founded in 2017 and is headquartered in Huzhou, China.
more
bullish•TYK Medicines
•08 Aug 2026 20:11

Primer: TYK Medicines (2410 HK) - Aug 2026

TYK Medicines is a clinical-stage biopharmaceutical company with a pipeline of over ten small molecule drug candidates focused on oncology,...

Share
•26 Sep 2026 14:08

China Healthcare Weekly Wrap (21-25 Sep)

We highlight 1) key studies to watch for upcoming October's ESMO updates, 2) deal flows Innocare/Lilly, BoomRay/Novartis, Earendil Labs...

Logo
95 Views
Share
•30 Aug 2026 08:30

APAC Healthcare Weekly (August 30)– CSPC Pharma, Akeso, Takeda, Astellas, Hanmi Pharm, SK Biopharma

CSPC and Akeso announced positive results from their respective Phase 3 trials for cancer drug candidates. Takeda got FDA approval for blood cancer...

Logo
103 Views
Share
•26 Jul 2026 11:28

China Healthcare Weekly Wrap (20-24 July)

SMMT 2Q26 on Akeso-partnered ivonescimab; positive profit alerts from Harbour, MicroPort MedBot, Shanghai HeartCare; Wuxi Bio hit 10,000 molecules;...

Logo
138 Views
Share
•29 Mar 2026 08:30

APAC Healthcare Weekly (March 29) – Hansoh, CSPC, Chugai, Takeda, Otsuka, Celltrion, Alteogen

Hansoh got trial approval, while CSPC obtained new drug approval. Chugai’s partner is discontinuing development of emugrobart. Otsuka is acquiring...

Logo
336 Views
Share
x